These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33943000)

  • 1. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
    Steegen K; Moorhouse M; Wensing AM; Venter WD; Hans L
    J Int AIDS Soc; 2021 May; 24(5):e25706. PubMed ID: 33943000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
    Sun Z; Lan Y; Liang S; Wang J; Ni M; Zhang X; Yu F; Chen M; Zhang H; Yan L; Cai W; Lan G; Ma Y; Zhang F
    J Antimicrob Chemother; 2022 Mar; 77(4):1119-1124. PubMed ID: 35134966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
    Rhee SY; Schapiro JM; Saladini F; Zazzi M; Khoo S; Shafer RW
    AIDS Res Ther; 2023 Feb; 20(1):8. PubMed ID: 36750835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
    Soulie C; Balde A; Fofana D; Charpentier C; Bonnafous P; Sourice J; De Monte A; Avettand-Fenoel V; Le Guillou-Guillemette H; Bocket L; Raymond S; Marque Juillet S; Trabaud MA; Montes B; Maillard A; Hartard C; Alessandri-Gradt E; Brochot E; Signori-Schmuck A; Assoumou L; Marcelin AG
    J Antimicrob Chemother; 2024 Aug; 79(8):1974-1984. PubMed ID: 38884154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
    Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
    J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.
    Reddy N; Papathanasopoulos M; Steegen K; Basson AE
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
    Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK
    J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
    Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
    Soulie C; Santoro MM; Charpentier C; Storto A; Paraskevis D; Di Carlo D; Gennari W; Sterrantino G; Zazzi M; Perno CF; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG
    J Antimicrob Chemother; 2019 Mar; 74(3):614-617. PubMed ID: 30476106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana.
    Bareng OT; Seselamarumo S; Seatla KK; Choga WT; Bakae B; Maruapula D; Kelentse N; Moraka NO; Mokaleng B; Mokgethi PT; Ditlhako TR; Pretorius-Holme M; Mbulawa MB; Lebelonyane R; Bile EC; Gaolathe T; Shapiro R; Makhema JM; Lockman S; Essex M; Novitsky V; Mpoloka SW; Moyo S; Gaseitsiwe S
    J Glob Antimicrob Resist; 2022 Dec; 31():128-134. PubMed ID: 35973671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
    Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
    J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A;
    Int J Antimicrob Agents; 2023 Mar; 61(3):106737. PubMed ID: 36708743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.